Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 99

1.

Iron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa.

Wang K, Peng B, Xiao J, Weinreb O, Youdim MBH, Lin B.

Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5287-5297. doi: 10.1167/iovs.17-22096.

PMID:
29049732
2.

The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.

Amit T, Bar-Am O, Mechlovich D, Kupershmidt L, Youdim MBH, Weinreb O.

Neuropharmacology. 2017 Sep 1;123:359-367. doi: 10.1016/j.neuropharm.2017.05.026. Epub 2017 May 29. Review.

PMID:
28571715
3.

The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.

Einoch R, Weinreb O, Mandiuk N, Youdim MBH, Bilker W, Silver H.

Eur Neuropsychopharmacol. 2017 May;27(5):470-483. doi: 10.1016/j.euroneuro.2017.03.005. Epub 2017 Apr 11.

PMID:
28410959
4.

Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells.

Liu W, Rabinovich A, Nash Y, Frenkel D, Wang Y, Youdim MBH, Weinreb O.

Neuropharmacology. 2017 Feb;113(Pt A):445-456. doi: 10.1016/j.neuropharm.2016.10.028. Epub 2016 Oct 28.

PMID:
27984078
5.

A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice.

Golko-Perez S, Amit T, Bar-Am O, Youdim MB, Weinreb O.

Neurotox Res. 2017 Feb;31(2):230-244. doi: 10.1007/s12640-016-9677-6. Epub 2016 Nov 8.

PMID:
27826939
6.

Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease.

Liu W, Lang M, Youdim MBH, Amit T, Sun Y, Zhang Z, Wang Y, Weinreb O.

Neuropharmacology. 2016 Oct;109:376-385. doi: 10.1016/j.neuropharm.2016.06.013. Epub 2016 Jun 16.

PMID:
27318273
7.

Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1(G93A) Transgenic ALS Mice.

Golko-Perez S, Amit T, Youdim MB, Weinreb O.

J Mol Neurosci. 2016 Aug;59(4):504-10. doi: 10.1007/s12031-016-0763-2. Epub 2016 May 13.

PMID:
27173029
8.

Mitochondria: old and new target in brain research.

Weinreb O.

J Neural Transm (Vienna). 2016 Feb;123(2):81-2. doi: 10.1007/s00702-015-1493-2. No abstract available.

PMID:
26666252
9.

Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.

Golko-Perez S, Mandel S, Amit T, Kupershmidt L, Youdim MB, Weinreb O.

Neurotox Res. 2016 Feb;29(2):208-17. doi: 10.1007/s12640-015-9574-4. Epub 2015 Nov 18.

PMID:
26581376
10.

The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease.

Pimentel LS, Allard S, Do Carmo S, Weinreb O, Danik M, Hanzel CE, Youdim MB, Cuello AC.

J Alzheimers Dis. 2015;47(2):373-83. doi: 10.3233/JAD-143126.

PMID:
26401560
11.

Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Br J Pharmacol. 2016 Jul;173(13):2080-94. doi: 10.1111/bph.13318. Epub 2015 Dec 1. Review.

12.

Effect of long-term treatment with rasagiline on cognitive deficits and related molecular cascades in aged mice.

Weinreb O, Badinter F, Amit T, Bar-Am O, Youdim MB.

Neurobiol Aging. 2015 Sep;36(9):2628-36. doi: 10.1016/j.neurobiolaging.2015.05.009. Epub 2015 May 21.

PMID:
26142126
13.

Beneficial behavioral, neurochemical and molecular effects of 1-(R)-aminoindan in aged mice.

Badinter F, Amit T, Bar-Am O, Youdim MB, Weinreb O.

Neuropharmacology. 2015 Dec;99:264-72. doi: 10.1016/j.neuropharm.2015.05.041. Epub 2015 Jun 15.

PMID:
26087462
14.

Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets.

Bar-Am O, Amit T, Youdim MB, Weinreb O.

J Neural Transm (Vienna). 2016 Feb;123(2):125-35. doi: 10.1007/s00702-015-1395-3. Epub 2015 Apr 10. Review.

PMID:
25859841
15.

Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients.

Silver H, Mandiuk N, Einoch R, Susser E, Danovich L, Bilker W, Youdim M, Weinreb O.

Int Clin Psychopharmacol. 2015 May;30(3):158-66. doi: 10.1097/YIC.0000000000000070.

PMID:
25756551
16.

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.

Bar-Am O, Amit T, Kupershmidt L, Aluf Y, Mechlovich D, Kabha H, Danovitch L, Zurawski VR, Youdim MB, Weinreb O.

Neurobiol Aging. 2015 Mar;36(3):1529-42. doi: 10.1016/j.neurobiolaging.2014.10.026. Epub 2014 Oct 22.

PMID:
25499799
17.

Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.

Mechlovich D, Amit T, Bar-Am O, Weinreb O, Youdim MB.

Br J Pharmacol. 2014 Dec;171(24):5636-49. doi: 10.1111/bph.12862.

18.
19.

DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline.

Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D.

J Neurochem. 2014 May;129(3):434-47. doi: 10.1111/jnc.12633. Epub 2014 Jan 6.

20.

Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.

Youdim MB, Kupershmidt L, Amit T, Weinreb O.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S132-6. doi: 10.1016/S1353-8020(13)70032-4. Review.

PMID:
24262165

Supplemental Content

Loading ...
Support Center